PROCESS-SYSTEMS-ENTERPRI
22.4.2016 16:46:03 CEST | Business Wire | Press release
At the 5th Advanced Process Modelling (APM) Forum in London this week, companies from across the process industries presented on topics ranging from accelerating development of the next generation of drugs to identifying hundreds of millions of Euros in operational savings in natural gas production.
Organised and hosted by Process Systems Enterprise (PSE), providers of the gPROMS APM platform, the two-day conference is a key event for process industry organisations focused on creating sustainable value through the application of high-accuracy predictive process modelling and optimisation.
In the sessions on formulated products, aimed at the pharmaceuticals, food & beverage, consumer goods and specialty chemicals sectors, presentations from AstraZeneca, Danone, Eli Lilly, Roche, Saint-Gobain, and Solvay described how new ‘digital design’ techniques are improving drug product manufacture, including development of robust continuous manufacturing processes, and accelerating time-to-market for new formulations.
A key event was the preview of PSE’s forthcoming gPROMS FormulatedProductsTM environment for integrated design and optimisation of formulated products and their manufacturing processes. Developed in co-operation with specialists from several sectors, this allows scientists and engineers to screen formulations for end-user attributes, determine whether they can be manufactured efficiently, and then use the gPROMS platform's optimisation capabilities to optimise the whole formulation and manufacturing chain.
In the oil & gas, chemicals, petrochemical & refining sessions, where presenters included Bharat Petroleum, BP Exploration, DSM, Primetals, SABIC, SCG Chemicals, Shell, Sulzer, Velocys and Yara International, the focus was on large-scale optimisation applications capable of improving profit by tens or hundreds of millions of Euros. These included major new developments in oilfield optimisation capable of identifying millions of dollars a day in increased production, Shell's work on region-wide optimisation of natural gas processing facilities, Bharat Petroleum’s innovative work in real-time optimisation of refinery crude transition, and DSM’s operational optimisation of the utility systems supplying electricity and steam to large-scale industrial sites. SABIC described how model-based analysis helped reduce the time to screen anti-coking technologies for ethylene production from years to months.
PSE MD Costas Pantelides said, “A key focus of the conference has been the coming of age of equation-oriented (EO) process modelling tools. EO is a disruptive technology that for the first time makes it possible to optimise large-scale, complex process systems using high-fidelity models and apply techniques such as global system analysis to explore the design and operational space much more rapidly than previously possible. This is enabling companies to realise large gains in competitive advantage and dramatically accelerate innovation”.
Keynote speaker Peter Drogt of DSM, standing in for Dorus van der Linden, said that advanced process modelling is crucial technology for the organisation to accelerate innovation and quantify process decisions. A key reason for the company’s move to APM is the ability to have a single unified modelling platform across the process lifecycle.
Editors: www.psenterprise.com/news/pr160422.html
View source version on businesswire.com: http://www.businesswire.com/news/home/20160422005717/en/
Contact:
Process Systems Enterprise
Kate Burness
+44-20-8563-0888
k.burness@psenterprise.com
Link:
Social Media:
https://www.facebook.com/pages/Process-Systems-Enterprise-Limited-PSE/194030330653358?ref=bookmarks
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
